SCHEMBL19852626

SCHEMBL19852626

CN(C)S(=O)(=O)n1cc(-c2ccccc2)cc1C=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.44
BRD4 O60885 1/20 0.37
LMNA P02545 3/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
ATM Q13315 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
SCD O00767 1/20 0.32
ALDH1A1 P00352 5/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KDM4E B2RXH2 2/20 0.31
GAA P10253 2/20 0.31
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31585892 0.72 BRD4 (0.58) BRD4LMNAATMALDH1A1KDM4E
SCHEMBL27315765 0.69 TSHR (0.44) TSHRTP53MAPTATMSMN1; SMN2
SCHEMBL1990134 0.68 BRD4 (0.41) BRD4LMNAATMALDH1A1KDM4E
SCHEMBL31586581 0.68 BRD4 (0.49) BRD4LMNAATMALDH1A1NPC1
SCHEMBL15033450 0.66 TSHR (0.47) TSHRLMNATP53MAPTATM
SCHEMBL2184244 0.66 TSHR (0.54) TSHRLMNATP53MAPTTHRB
SCHEMBL6420842 0.62 KDM4E (0.48) TSHRLMNANPSR1SMN1; SMN2ALDH1A1
SCHEMBL7512027 0.62 TSHR (0.54) TSHRMAPTSMN1; SMN2ALDH1A1L3MBTL1
Biphenyl SCHEMBL27184952 0.62 ALDH1A1 (0.45) TSHRMAPTSMN1; SMN2ALDH1A1KDM4E
Biphenyl SCHEMBL27802171 0.61 ALDH1A1 (0.50) TSHRLMNAMAPTRECQLNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS, INC. (US) 2020-02-18 US disclosed
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS SUNOVION PHARMACEUTICALS INC. 2018-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180037590-A1 SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS PDE10A, PDE2A, PDE3A TSHR 2306/4885BRD4 154/4885LMNA 3470/4885
US-10562916-B2 Substituted quinoxalines as PDE-10 inhibitors PDE4A, PDE2A, PDE9A TSHR 2874/4885BRD4 1105/4885LMNA 3129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.